Figure 1.

Kaplan–Meier survival curves. (A) Biochemical failure‐free survival (BFFS) and (B) distant metastasis‐free survival (DMFS) of patients who underwent low‐dose‐rate prostate brachytherapy according to the level of prostate‐specific antigen nadir within 12 months (nPSA12). (C) BFFS and (D) DMFS of patients who underwent external beam radiotherapy (EBRT) according to nPSA12. There were significant differences in these outcomes between patients with a low nPSA12 (≤median) and those with a high nPSA12 (>median). CI, confidence interval.